Medtronic receives fda clearance for new inpen™ app, paving the way for its smart mdi system launch with simplera™ cgm

New smart mdi system will be the first system to deliver real-time, personalized insights on when and how much to dose including for missed or inaccurate mealtime doses. galway, ireland , nov. 20, 2024 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced u.s. food and drug administration (fda) clearance for its new inpen™ app featuring missed meal dose detection, paving the way for the launch of its smart mdi system with the simplera™ continuous glucose monitor (cgm).
MDT Ratings Summary
MDT Quant Ranking